Related to Icagen Lands One-Year, $5M Extension to Pfizer Collaboration for Pain Therapies

• Pfizer to Re-Test Failed Melanoma Drug in Phase III with Debiopharm
  
• DxS to Develop Companion Diagnostic for Pfizer’s Phase II Brain Cancer Candidate
  
• Tocris and Sigma-Aldrich to Supply Pfizer Molecules for Research Use
  
• JDRF, Pfizer, Hadassah Medical, and The Hebrew University Forge Type 1 Diabetes Pact
  
• Sage and Pfizer Team Up on Cancer Research
  
• Pfizer to Assess Tekmira Technology to Deliver siRNAs in Preclinical Models
  
• Stemgent to Supply Stem Cell Related Reagents from Pfizer
  
• Pfizer and MMV to Take Preventive Malaria Treatment for Pregnant Women into Phase III This Year
  
• Trials Halted as Pfizer's Tanezumab Shown to Worsen Osteoarthritis
  
• Pfizer to Study Liver Cancer in Korean Patients with Samsung Medical Center
  
• Pfizer Axes Two More Pain Trials with Tanezumab
  
• Icagen Stops Epilepsy Trial with Ion-Channel Drug after Serious Adverse Event
  
• Pfizer Inks Deal with K.U. Leuven for HIV Drugs with New Mechanism of Action
  
• Pfizer to Pony Up $3.6B for King Pharmaceuticals
  
• Pfizer Pays Biocon $200M Up Front in Global Marketing Agreement for Diabetes Therapies
  
• FDA Clears Fifth Indication for Lilly's Cymbalta as Treatment for Musculoskeletal Pain
  
• Ablynx Earns $3M from Pfizer as Second Anti-TNF-Alpha Nanobody Enters Clinic
  
• Pfizer Taps Biovista for Drug Repositioning Capabilities
  
• Pfizer Taps Academia with Launch of Global Centers for Therapeutic Innovation
  
• Convergence and Selcia to Develop Ion Channel Drugs for Pain